# Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Article · Steven P. Marso, Stephen Charles Bain, Agostino Consoli, Freddy Goldberg Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent C. Woo, Oluf H. Hansen, Anders Gaarsdal Holst, Jonas Pettersson, Tina Vilsbøll

- Archive id: doi:10.1056/nejmoa1607141
- Published: 2016-09-16
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa1607141
- PMID: 27633186
- Citations: 6,888
- Source URL: https://doi.org/10.1056/nejmoa1607141
- PDF: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607141?articleTools=true
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.